Five-year relative survival and determinants of excess mortality in patients with head and neck and thyroid cancers: A population-based study from Golestan province,Northern Iran |
| |
| Institution: | 1. Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran;2. Department of Statistics and Information Technology, Golestan University of Medical Sciences, Gorgan, Iran;3. Deputy of Public Health, Golestan University of Medical Sciences, Gorgan, Iran;4. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran;5. Office of the Director, International Agency for Research on Cancer (IARC), Lyon, France;6. Omid Cancer Research Center, Omid Preventive Medicine and Heath Promotion Center, Golestan University of Medical Sciences, Gorgan, Iran;1. Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, VT, USA;2. Biomedical Statistics Research Core, University of Vermont, Burlington, VT, USA;3. Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, USA;1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615N. Wolfe Street, Baltimore, MD 21205, USA;2. Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21205, USA;1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China;2. Hotan District People’s Hospital, Hotan, Xinjiang 848000, China;1. Gastrointestinal & Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran;2. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran;3. Student Research Committee, Larestan University of Medical Sciences, Larestan, Iran;4. Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran;5. Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran;6. Zabol University of Medical Sciences, Zabol, Iran;7. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran;8. Iranian Center of Excellence in Health Management, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran;9. Research Center for Health Sciences, Institute of Health, Epidemiology Department, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran;1. Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia;2. Douglass Hanly Moir Pathology, Macquarie Park and Department of Clinical Medicine, Faculty of Medicine, Health and Human Science, Macquarie University, Sydney, Australia;3. Cancer Epidemiology Division, Cancer Council Victoria, and Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia;4. Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia;5. Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia;6. St. Vincent''s Hospital, Sydney and University of New South Wales, Sydney, New South Wales, Australia;7. Department of Haematology, Prince of Wales Hospital and University of New South Wales, Sydney, New South Wales, Australia;8. Concord Repatriation General Hospital and University of Sydney, Concord, New South Wales, Australia;9. Clinical Haematology, Monash Health and Monash University, Clayton, Australia;10. New South Wales Health Pathology and University of New South Wales, Sydney, New South Wales, Australia;11. St. George Hospital, Kogarah and University of New South Wales, Sydney, New South Wales, Australia;12. Liverpool Hospital, Liverpool and Western Sydney University, New South Wales, Australia;13. Gosford Hospital and The University of Newcastle, New South Wales, Australia;14. Rural Medical School and Border Medical Oncology Research Unit, Albury, New South Wales, Australia;15. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia;p. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia;q. The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia |
| |
| Abstract: | BackgroundWe aimed to assess relative survival (RS) and determinants of excess mortality rate in patients with head and neck squamous cell carcinomas (HNSCC) and thyroid cancer in Golestan province, Northern Iran.MethodsWe recruited new primary HNSCC and thyroid cancer cases from Golestan, 2006–2016. Five-year age-standardized RS with their 95% confidence intervals (CIs) were calculated. The relationships between different variables with excess mortality rates were assessed by estimating adjusted excess hazard ratios (aEHRs) with their 95% CIs.ResultsOverall, 718 cases of HNSCC and 386 thyroid cancer cases were enrolled. Five-year age-standardized RS (95% CI) were 36% (31−41) and 61% (52−69) in HNSCC and thyroid cancer patients, respectively. There were significant relationship between excess mortality rates in HNSCC patients with metastasis (aEHR= 3.31; 95%CI: 2.26–4.84), treatment type (4.19; 2.54–6.91, for no treatment as compared to receiving both surgery and chemoradiotherapy), age (2.16; 1.57–2.96, for older age group) and smoking (2.00; 1.45–2.75, for smokers as compared to non-smokers). Determinant of the excess mortality in thyroid cancer patients included metastasis (19.65; 8.08–47.79), tumor morphology (12.27; 4.62–32.58, for anaplastic cancer as compared to papillary cancer), treatment type (8.95, 4.13–19.4, for no treatment as compared to receiving both surgery and iodine therapy) and age (2.31; 1.17–4.54, for older age group).ConclusionOur findings suggested low RS for thyroid cancer in our population, while the estimates for HNSCC were comparable with other population. Metastasis, treatment type and age were determinants of mortality both in thyroid and HNSCC patients. |
| |
| Keywords: | Relative survival Head and neck Thyroid Cancer Iran |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
